Abstract: Compositions and methods for therapeutic delivery are disclosed. More particularly, the present disclosure relates to nanoparticle compositions that sequester the activity of a target molecule while leaving other domains accessible to bind targeted tissues of interest. Methods for thrombus dissolution include administering a nanoparticle reversibly coupled to a target molecule that can dissolve a blood clot. Compositions and methods for inducing blood clotting are also disclosed. Methods for inducing blood clotting include administering a nanoparticle reversibly coupled to a target molecule that can induce the formation of a blood clot. Methods for sequestering a target molecule are also disclosed. The method includes reversibly coupling a target molecule to a nanoparticle having an affinity ligand that reversibly couples the target molecule, and thus, sequesters the target molecule activity until the target molecule interacts with its substrate resulting in the release of the target molecule.

Abstract: Compositions and methods for therapeutic delivery are disclosed. More particularly, the present disclosure relates to nanoparticle compositions that sequester the activity of a target molecule while leaving other domains accessible to bind targeted tissues of interest. Methods for thrombus dissolution include administering a nanoparticle reversibly coupled to a target molecule that can dissolve a blood clot. Compositions and methods for inducing blood clotting are also disclosed. Methods for inducing blood clotting include administering a nanoparticle reversibly coupled to a target molecule that can induce the formation of a blood clot. Methods for sequestering a target molecule are also disclosed. The method includes reversibly coupling a target molecule to a nanoparticle having an affinity ligand that reversibly couples the target molecule, and thus, sequesters the target molecule activity until the target molecule interacts with its substrate resulting in the release of the target molecule.

Abstract: Compositions and methods for therapeutic delivery are disclosed. More particularly, the present disclosure relates to nanoparticle compositions that sequester the activity of a target molecule while leaving other domains accessible to bind targeted tissues of interest. Methods for thrombus dissolution include administering a nanoparticle reversibly coupled to a target molecule that can dissolve a blood clot. Compositions and methods for inducing blood clotting are also disclosed. Methods for inducing blood clotting include administering a nanoparticle reversibly coupled to a target molecule that can induce the formation of a blood clot. Methods for sequestering a target molecule are also disclosed. The method includes reversibly coupling a target molecule to a nanoparticle having an affinity ligand that reversibly couples the target molecule, and thus, sequesters the target molecule activity until the target molecule interacts with its substrate resulting in the release of the target molecule.

Abstract: Compositions and methods for therapeutic delivery are disclosed. More particularly, the present disclosure relates to nanoparticle compositions that sequester the activity of a target molecule while leaving other domains accessible to bind targeted tissues of interest. Methods for thrombus dissolution include administering a nanoparticle reversibly coupled to a target molecule that can dissolve a blood clot. Compositions and methods for inducing blood clotting are also disclosed. Methods for inducing blood clotting include administering a nanoparticle reversibly coupled to a target molecule that can induce the formation of a blood clot. Methods for sequestering a target molecule are also disclosed. The method includes reversibly coupling a target molecule to a nanoparticle having an affinity ligand that reversibly couples the target molecule, and thus, sequesters the target molecule activity until the target molecule interacts with its substrate resulting in the release of the target molecule.

Abstract: The present disclosure provides a method and system for estimating the clinical responsiveness of a patient to a dose of a plasminogen activating agent to treat a thrombosis, comprising determining a concentration of ?2-antiplasmin in a blood sample of the patient, determining a concentration of activated fibrinolysis inhibitor (“TAFI”) in the blood sample, determining a concentration of plasminogen activator Inhibitor 1 (“PAI-1”) in the blood sample, computing a clot lysis time (“CLT”) based on the concentrations of a2-antiplasmin, TAFI and PAI-1 using the equation CLT=?2,813.6+31.1*a2-antiplasmin (percent activity)+31.1*TAFI (percent activity)+1.49 PAI-1 (ug/L), and determining that the patient is at increased risk of hemorrhage when the computed CLT is less than a first predetermined cutoff time.

Abstract: Compositions and methods for therapeutic delivery are disclosed. More particularly, the present disclosure relates to nanoparticle compositions that sequester the activity of a target molecule while leaving other domains accessible to bind targeted tissues of interest. Methods for thrombus dissolution include administering a nanoparticle reversibly coupled to a target molecule that can dissolve a blood clot. Compositions and methods for inducing blood clotting are also disclosed. Methods for inducing blood clotting include administering a nanoparticle reversibly coupled to a target molecule that can induce the formation of a blood clot. Methods for sequestering a target molecule are also disclosed. The method includes reversibly coupling a target molecule to a nanoparticle having an affinity ligand that reversibly couples the target molecule, and thus, sequesters the target molecule activity until the target molecule interacts with its substrate resulting in the release of the target molecule.

Abstract: A breath condensate collection apparatus comprising a central chamber, a breath input assembly, a plunger assembly and a breath condensate collection port. The central chamber has inner and outer side walls with a coolant material sealed in between. The breath input assembly is disposed on the side of the central chamber in fluid communication with the chamber interior. The plunger assembly has a piston, slidably disposed in the chamber, and a handle extending from a first end of the chamber. The collection port is disposed at the second end of the central chamber in fluid communication with the interior of the chamber. Obstructive structures may be arranged in the chamber interior for increasing the surface area on which condensate may form. The apparatus may also include an outlet assembly that may be removed and replaced with a sampling well into which the condensate may be washed with a buffer solution.

Abstract: An automatic daylighting method adjusts a window covering to block direct sunlight from entering the room through a window when the exterior sky condition is a sunny sky state and, subject to blocking direct sunlight, provides a desired daylighting interior light illuminance level and, if possible, a desired interior solar heat gain through the window. To prevent window covering oscillation, a delay may be used when the sky condition changes from a sunny to overcast state. The covering control may be based on various factors including interior light illuminance entering the window, a room heating or to cooling mode, whether the room is occupied by people, whether occupants have manually operated an adjustable window covering, and the exterior sky condition. The method may also detect an interior temperature level, e.g., to determine a heating or cooling mode of the room.

Abstract: A computer-based device and predictive model executable by computer software for use with the device to predict or estimate a percentage probability of death from thrombosis in a patient with active cancer.

Abstract: A method of determining the presence of pulmonary embolism is a postoperative patient using the carbox ratio of the patient prior to the surgical procedure and the carbox ratio of the patient after to the surgical procedure. The characteristics of the breath of the patient are obtained prior to a surgical procedure for a baseline and then afterwards if the patient has difficult breathing. The mean carbox ratios from the baseline and post-surgical data collections are then compared to non-invasively predict the likelihood that the patient has developed pulmonary embolism. A decrease in the carbox ratio of more than twenty-five percent (25%) represents an abnormal test and is consistent with possible pulmonary embolism. No change or an increase in the carbox ratio suggests the absence of pulmonary embolism.

Abstract: An automatic daylighting method adjusts a window covering to block direct sunlight from entering the room through a window when the exterior sky condition is a sunny sky state and, subject to blocking direct sunlight, provides a desired daylighting interior light illuminance level and, if possible, a desired interior solar heat gain through the window. To prevent window covering oscillation, a delay may be used when the sky condition changes from a sunny to overcast state. The covering control may be based on various factors including interior light illuminance entering the window, a room heating or to cooling mode, whether the room is occupied by people, whether occupants have manually operated an adjustable window covering, and the exterior sky condition. The method may also detect an interior temperature level, e.g., to determine a heating or cooling mode of the room.

Abstract: A method and a test for using carbonic anhydrase (CA), particularly CA-I or CA-II, as a biomarker of hemolysis. The method and test detect hemolysis by determining a percentage erythrocyte hemolysis in a specimen or sample of blood based upon quantification of carbonic anhydrase present in the extracellular portion of the blood. The method and test serve to optimize therapeutic efficacy for treatments of hemolysis. Plasma carbonic anhydrase is used to determine the percentage hemolysis in plasma. Furthermore, CA is quantified with specificity to the isozyme present in the plasma.

Abstract: A method for determining whether a subject has Gram negative bacterial pneumonia based on the presence of lipopolysaccharide in exhaled breath condensate collected from the subject. The collection devices utilized to collect exhaled breath condensate from both spontaneously breathing and mechanically ventilated subjects and the devices utilized to determine whether lipopolysaccharide is present in the collected exhaled breath condensate.

Abstract: A method for determining whether a subject has Gram negative bacterial pneumonia based on the presence of lipopolysaccharide in exhaled breath condensate collected from the subject. The collection devices utilized to collect exhaled breath condensate from both spontaneously breathing and mechanically ventilated subjects and the devices utilized to determine whether lipopolysaccharide is present in the collected exhaled breath condensate.

Abstract: A diagnosis method for respiratory disease based on the separation of the expired airway phase in an exhaled breath from the alveolar phase, and a device to accomplish the method. The device includes a cartridge assembly and a disposable condensing chamber carried in a substantially enclosed housing. The cartridge assembly includes a disposable cartridge and a reusable control system that monitors a characteristic of gas passing through the cartridge to determine when to divert the exhaled breath to an exhaust outlet and when to divert the exhaled breath to the condensing chamber. The characteristic is selected as being representative of the transition from the expired airway phase to the alveolar phase. Also included are a refrigeration system, an auxiliary monitoring system for determining when a sufficient volume of gas has been produced, and a built-in analyzer.

Abstract: The invention involves a device and method for ascertaining the functioning of the respiratory system and determining the cause of abnormal respiratory function. The device comprises an apparatus for measuring the flow of air from a patient's breadth and determining the concentration of gases contained therein via real-time spectrometry. From this data, a processor computes the ratio of detected gases relative to each other and as a function of expired volume and plots the calculations on a display screen. Based on various plots, a physician can more easily estimate the probability of a number of pulmonary diseases and afflictions, such pulmonary embolism, emphysema, congestive heart failure, infection, and related problems.

Abstract: The invention involves a device and method for ascertaining the functioning of the respiratory system and, in particular, determining the cardiac output of a patient. The device comprises an apparatus containing sensors for measuring the oxygen and carbon dioxide concentrations as well as the volume of air inhaled and exhaled by a patient. The patient is provided a mouthpiece for breathing into and out of the device, which subsequently measures oxygen partial pressures of the inhaled and exhaled air. In addition, the patient's arterial oxygen saturation is continuously measured through pulse oximetry and the pH and hemoglobin concentration is determined from a venous blood sample. From this data, the cardiac output of the patient may be calculated.

Abstract: A breath condensate collection apparatus comprising a central chamber, a breath input assembly, a plunger assembly and a breath condensate collection port. The central chamber has inner and outer side walls with a coolant material sealed in between. The breath input assembly is disposed on the side of the central chamber in fluid communication with the chamber interior. The plunger assembly has a piston, slidably disposed in the chamber, and a handle extending from a first end of the chamber. The collection port is disposed at the second end of the central chamber in fluid communication with the interior of the chamber. Obstructive structures may be arranged in the chamber interior for increasing the surface area on which condensate may form. The apparatus may also include an outlet assembly that may be removed and replaced with a sampling well into which the condensate may be washed with a buffer solution.

Abstract: A method and system for detecting the presence of restriction to expired airflow in humans or animals by analyzing the expired capnogram and oxygram, as well as the geometric analysis of the real-time plot of the waveform that depicts the instantaneous ratio of CO2 to O2 (the carboxygram ratio). Airway obstructions causes an increase in the Q-angle between the slope of phase 11 and slope of phase III in the expired carboxygram. The diagnostic accuracy of the detection of airways obstruction is further enhanced by measuring the ratio of time spent in exhalation (Te) versus inhalation (Ti). The system uses the combination of an increased carboxygram Q-angle, and a prolonged Te/Ti to detect presence of airways obstruction.

Abstract: A diagnosis method for respiratory disease based on the separation of the expired airway phase in an exhaled breath from the alveolar phase, and a device to accomplish the method. The device includes a cartridge assembly and a disposable condensing chamber carried in a substantially enclosed housing. The cartridge assembly includes a disposable cartridge and a reusable control system that monitors a characteristic of gas passing through the cartridge to determine when to divert the exhaled breath to an exhaust outlet and when to divert the exhaled breath to the condensing chamber. The characteristic is selected as being representative of the transition from the expired airway phase to the alveolar phase. Also included are a refrigeration system, an auxiliary monitoring system for determining when a sufficient volume of gas has been produced, and a built-in analyzer.